Trials / Completed
CompletedNCT04324814
A Trial of SHR-1701 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Multi-Center, Non-Randomized, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SHR-1701 in Subjects With Advanced Solid Tumors.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Atridia Pty Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and tolerability of SHR-1701 in subjects with advanced solid tumors.
Detailed description
This is a two-part, open-label, multicenter, non-randomized, dose escalation, Phase 1 study of repeated doses of SHR-1701 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701 | Anti-PD-L1/TGFβ fusion protein |
Timeline
- Start date
- 2020-03-31
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
- First posted
- 2020-03-27
- Last updated
- 2023-02-21
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT04324814. Inclusion in this directory is not an endorsement.